As of Tuesday, Recursion Pharmaceuticals Inc.’s (NASDAQ:RXRX) stock closed at $8.59, down from $8.71 the previous day. While Recursion Pharmaceuticals Inc. has underperformed by -1.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RXRX fell by -23.64%, with highs and lows ranging from $14.18 to $4.92, whereas the simple moving average fell by -3.10% in the last 200 days.
On September 16, 2022, KeyBanc Capital Markets started tracking Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) recommending Overweight. A report published by BofA Securities on April 18, 2022, Downgraded its rating to ‘Neutral’ for RXRX. SVB Leerink also Downgraded RXRX shares as ‘Mkt Perform’, setting a target price of $10 on the company’s shares in a report dated March 04, 2022. Berenberg Initiated an Buy rating on September 21, 2021, and assigned a price target of $37. SVB Leerink initiated its ‘Outperform’ rating for RXRX, as published in its report on May 11, 2021. KeyBanc Capital Markets’s report from May 11, 2021 suggests a price prediction of $36 for RXRX shares, giving the stock a ‘Overweight’ rating. JP Morgan also rated the stock as ‘Neutral’.
Analysis of Recursion Pharmaceuticals Inc. (RXRX)
Further, the quarter-over-quarter increase in sales is 428.00%, showing a positive trend in the upcoming months.
One of the most important indicators of Recursion Pharmaceuticals Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -53.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.80, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RXRX is recording 1.26M average volume. On a monthly basis, the volatility of the stock is set at 6.60%, whereas on a weekly basis, it is put at 6.01%, with a loss of -6.43% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.17, showing growth from the present price of $8.59, which can serve as yet another indication of whether RXRX is worth investing in or should be passed over.
How Do You Analyze Recursion Pharmaceuticals Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.50%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.70% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in RXRX shares?
The recent increase in stakes in RXRX appears to be a result of several institutional investors and hedge funds increasing their positions. Baillie Gifford & Co.’s position in RXRX has decreased by -0.05% in the first quarter. The company now owns 21,594,693 shares of the stock, with a value of $166.5 million, following the sale of -10,992 additional shares during the last quarter. During the last quarter, the company picked up 0 additional shares for a total stake of worth $65.16 million, bringing number of shares owned by the company to 8,451,758.
During the first quarter, BlackRock Fund Advisors added a 1,476,128 position in RXRX. The Vanguard Group, Inc. purchased an additional 1.35 million shares in the last quarter, increasing its holdings by 19.79%, now holding 8.2 million shares worth $63.24 million. RXRX shares are owned by institutional investors to the tune of 68.70% at present.